دورية أكاديمية
Pharma[e]cology: How the Gut Microbiome Contributes to Variations in Drug Response.
| العنوان: | Pharma[e]cology: How the Gut Microbiome Contributes to Variations in Drug Response. |
|---|---|
| المؤلفون: | Trepka KR; 1Department of Microbiology & Immunology, University of California, San Francisco, California, USA; email: peter.turnbaugh@ucsf.edu., Olson CA; 1Department of Microbiology & Immunology, University of California, San Francisco, California, USA; email: peter.turnbaugh@ucsf.edu., Upadhyay V; 1Department of Microbiology & Immunology, University of California, San Francisco, California, USA; email: peter.turnbaugh@ucsf.edu.; 2Department of Medicine, University of California, San Francisco, California, USA., Zhang C; 1Department of Microbiology & Immunology, University of California, San Francisco, California, USA; email: peter.turnbaugh@ucsf.edu., Turnbaugh PJ; 1Department of Microbiology & Immunology, University of California, San Francisco, California, USA; email: peter.turnbaugh@ucsf.edu.; 3Chan Zuckerberg Biohub-San Francisco, San Francisco, California, USA. |
| المصدر: | Annual review of pharmacology and toxicology [Annu Rev Pharmacol Toxicol] 2024 Aug 06. Date of Electronic Publication: 2024 Aug 06. |
| Publication Model: | Ahead of Print |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Annual Reviews Country of Publication: United States NLM ID: 7607088 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1545-4304 (Electronic) Linking ISSN: 03621642 NLM ISO Abbreviation: Annu Rev Pharmacol Toxicol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Palo Alto Ca : Annual Reviews Original Publication: Palo Alto, Calif., Annual Reviews. |
| مستخلص: | Drugs represent our first, and sometimes last, line of defense for many diseases, yet despite decades of research we still do not fully understand why a given drug works in one patient and fails in the next. The human gut microbiome is one of the missing puzzle pieces, due to its ability to parallel and extend host pathways for drug metabolism, along with more complex host-microbiome interactions. Herein, we focus on the well-established links between the gut microbiome and drugs for heart disease and cancer, plus emerging data on neurological disease. We highlight the interdisciplinary methods that are available and how they can be used to address major remaining knowledge gaps, including the consequences of microbial drug metabolism for treatment outcomes. Continued progress in this area promises fundamental biological insights into humans and their associated microbial communities and strategies for leveraging the microbiome to improve the practice of medicine. |
| تواريخ الأحداث: | Date Created: 20240806 Latest Revision: 20240806 |
| رمز التحديث: | 20240807 |
| DOI: | 10.1146/annurev-pharmtox-022724-100847 |
| PMID: | 39107044 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1545-4304 |
|---|---|
| DOI: | 10.1146/annurev-pharmtox-022724-100847 |